Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR).

Gampenrieder, SP; Peer, A; Weismann, C; Meissnitzer, M; Rinnerthaler, G; Webhof-er, J; Westphal, T; Riedmann, M; Meissnitzer, T; Egger, H; Klaassen Federspiel, F; Reitsamer, R; Hauser-Kronberger, C; Stering, K; Hergan, K; Mlineritsch, B; Greil, R. Breast Cancer Res. 2019 Jan 31;21(1):19. doi: 10.1186/s13058-018-1091-y.

Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a rando-mised, double-blind, placebo-controlled, phase 3 trial.

Gnant, M; Pfeiler, G; Steger, GG; Egle, D; Greil, R; Fitzal, F; Wette, V; Balic, M; Hasl-bauer, F; Melbinger-Zeinitzer, E; Bjelic-Radisic, V; Jakesz, R; Marth, C; Sevelda, P; Mlineritsch, B; Exner, R; Fesl, C; Frantal, S; Singer, CF. Lancet Oncol. 2019 Mar;20(3):339-351. doi: 10.1016/S1470-2045(18)30862-3. Epub 2019 Feb 19.

Baseline Absolute Lymphocyte Count and ECOG Performance Score Are Associated with Survival in Advanced Non-Small Cell Lung Cancer Undergoing PD-1/PD-L1 Blockade.

Huemer, F; Lang, D; Westphal, T; Gampenrieder, SP; Hutarew, G; Weiss, L; Hackl, H; Lamprecht, B; Rinnerthaler, G; Greil, R. J Clin Med. 2019 Jul 10;8(7):1014. doi: 10.3390/jcm8071014.

Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and/or BIM.

Huemer, F; Melchardt, T; Jansko, B; Wahida, A; Jilg, S; Jost, PJ; Klieser, E; Katja, S; Magnes, T; Pleyer, L; Greil-Ressler, S; Rass, C; Greil, R; Egle, A. Eur J Haematol. 2019 May;102(5):437-441. doi: 10.1111/ejh.13218. Epub 2019 Feb 28.

Association between antibiotics use and outcome in patients with NSCLC trea-ted with immunotherapeutics.

Huemer, F; Rinnerthaler, G; Lang, D; Hackl, H; Lamprecht, B; Greil, R. Ann Oncol. 2019 Apr 1;30(4):652-653. doi: 10.1093/annonc/mdz021.

Regorafenib Is Associated With Increased Skeletal Muscle Loss Compared to TAS-102 in Metastatic Colorectal Cancer.

Huemer, F; Schlintl, V; Hecht, S; Hackl, H; Melchardt, T; Rinnerthaler, G; Greil, R; Weiss, L. Clin Colorectal Cancer. 2019 Jun;18(2):159-166.e3. doi: 10.1016/j.clcc.2019.04.003. Epub 2019 Apr 11.

Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study.

Lang, D; Huemer, F; Rinnerthaler, G; Horner, A; Wass, R; Brehm, E; Akbari, K; Gra-nitz, M; Hutarew, G; Kaiser, B; Greil, R; Lamprecht, B. Target Oncol. 2019 Dec;14(6):707-717. doi: 10.1007/s11523-019-00679-9.

Plitidepsin: a potential new treatment for relapsed/refractory multiple myeloma.

Leisch, M; Egle, A; Greil, R. Future Oncol. 2019 Jan;15(2):109-120. doi: 10.2217/fon-2018-0492. Epub 2018 Aug 16.

Next Generation Sequencing in AML-On the Way to Becoming a New Standard for Treatment Initiation and/or Modulation?

Leisch, M; Jansko, B; Zaborsky, N; Greil, R; Pleyer, L. Cancers (Basel). 2019 Feb 21;11(2):252. doi: 10.3390/cancers11020252.

Large platelet size is associated with poor outcome in patients with metastatic pancreatic cancer.

Lembeck, AL; Posch, F; Klocker, EV; Szkandera, J; Schlick, K; Stojakovic, T; Korn-prat, P; Lackner, C; Gerger, A; Stoeger, H; Stotz, M; Pichler, M. Clin Chem Lab Med. 2019 Apr 24;57(5):740-744. doi: 10.1515/cclm-2018-0016.